Clinical indications for genetic testing in familial sudden cardiac death syndromes: An HRUK position statement

Heart

Volumn 94, Issue 4, 2008, Pages 502-507

  Garratt, C J ^a,b   Elliott, P ^c   Behr, E ^d   Blair, E ^e   Connelly, D ^f   Cowan, C ^g   Davidson, N ^h   Grace, A ⁱ   Griffith, M ^j   Jolly, A ^f   Lambiase, P ^c   McKenna, W ^k  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ST GEORGE S HOSPITAL   (United Kingdom)

^e CHURCHILL HOSPITAL   (United Kingdom)

^f Heart Rhythm ^*  (United Kingdom)

^g Heart Improvement Programme   (United Kingdom)

^h WYTHENSHAWE HOSPITAL   (United Kingdom)

ⁱ PAPWORTH HOSPITAL   (United Kingdom)

^j QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^k UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRUGADA SYNDROME; CARDIOMYOPATHY; COST EFFECTIVENESS ANALYSIS; ELECTROCARDIOGRAM; FAMILIAL DISEASE; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC HETEROGENEITY; GENETIC SCREENING; HEART DEATH; HUMAN; INHERITANCE; LONG QT SYNDROME; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SUDDEN DEATH;

ADULT; AGE FACTORS; COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; EVIDENCE-BASED MEDICINE; GENETIC COUNSELING; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEART DISEASES; HUMANS; PATIENT SELECTION; SENSITIVITY AND SPECIFICITY;

EID: 41149114636     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.127761     Document Type: Review

References (40)

1. Coronary Heart Disease. National Service Framework. Chapter Eight. Arrhythmias and sudden cardiac death.London: Department of Health, March 2005.
2. AGREE Tool. http://www.agreecollaboration.org (accessed 18 November 2007).
3. Phillips KA, Ackerman MJ, Sakowski J, et al. Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases. Heart Rhythm 2005;2:1294-300.
4. Priori SG, Napolitano C. Role of genetic analyses in cardiology: Part I: Mendelian diseases: cardiac channelopathies. Circulation 2006;113:1130-5.
5. Behr E, Wood DA, Wright M, et al. Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome. Lancet 2003;362:1457-9.
6. Tan HL, Hofman N, van Langen IM, et al. Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. Circulation 2005;112:207-13.
7. Tester DJ, Ackerman MJ. The role of molecular autopsy in unexplained sudden cardiac death. Curr Opin Cardiol 2006;21:166- 72.
8. Priori SG, Barhanin J, Hauer RN, et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation 1999;99:518-28.
9. Tester DJ, Spoon DB, Valdivia HH, et al. Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular autopsy of 49 medical examiner/coroner's cases. Mayo Clin Proc 2004;79:1380-4.
10. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002;106:69-74.
11. Chugh SS, Senashova O, Watts A, et al. Postmortem molecular screening in unexplained sudden death. J Am Coll Cardiol 2004;43:1625-9.
12. Di PM, Luchini D, Bloise R, et al. Postmortem molecular analysis in victims of sudden unexplained death. Am J Forensic Med Pathol 2004;25:182-4.
13. Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993;88:782-4.
14. Ackerman MJ. Genetic testing for risk stratification in hypertrophic cardiomyopathy and long QT syndrome: fact or fiction? Curr Opin Cardiol 2005;20:175-81.
15. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-pheotype correlation in the long QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001;103:89-95.
16. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004;292:1341-4.
17. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348: 1866-74.
18. Schwartz PJ, Spazzolini C, Crotti L, et al. The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation 2006;113:783-90.
19. Splawski I, Timothy KW, Sharpe LM, et al. Ca(V) 1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004;119:19-31.
20. Tristani-Firouzi M, Jensen JL, Donaldson MR, et al. Functional and clinical characetrisation of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 2002;110:381-8.
21. Lahat H, Pras E, Eldar M. RYR2 and CASQ2 mutations in patients suffering from catecholaminergic polymorphic ventricular tachycardia. Circulation 2003;107:e29.
22. Eldar M, Pras E, Lahat H. A missense mutation in the CASQ2 gene is associated with autosomal-recessive catecholamine-induced polymorphic ventricular tachycardia. Trends Cardiovasc Med 2003;13:148-51.
23. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001;103:196-200.
24. Tester DJ, Kopplin LJ, Will ML, et al. Spectrum and prevalence of cardiac ryanodine receptor (RyR2) mutations in a cohort of unrelated patients referred explicitly for long QT syndrome genetic testing. Heart Rhythm 2005;2:1099-105.
25. Francis J, Sankar V, Nair VK, et al. Catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2005;2:550-4.
26. Sumitomo N, Harada K, Nagashima M, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 2003;89:66-70.
27. Arbustini E, Pilotto A, Repetto A, et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease. J Am Coll Cardiol 2002;39:981-90.
28. Antzelevitch C. The Brugada syndrome. J Cardiovasc Electrophysiol 1998;9:513-6.
29. Baroudi G, Pouliot V, Denjoy I, et al. Novel mechanism for Brugada syndrome: defective surface localization of an SCN5A mutant (R1432G). Circ Res 2001;88:E78-83.
30. Hong K, Guerchicoff A, Pollevick GD, et al. Cryptic 5′ splice site activation in SCN5A associated with Brugada syndrome. J Mol Cell Cardiol 2005;38:555-60.
31. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001;104:3081-6.
32. Makiyama T, Akao M, Tsuji K, et al. High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCN5A gene mutations. J Am Coll Cardiol 2005;46:2100-6.
33. Schulze-Bahr E, Eckardt L, Breithardt G, et al. Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat 2003;21:651-2.
34. Shin DJ, Jang Y, Park HY, et al. Genetic analysis of the cardiac sodium channel gene SCN5A in Koreans with Brugada syndrome. J Hum Genet 2004;49:573-8.
35. Meregalli PG, Ruijter JM, Hofman N, et al. Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. J Cardiovasc Electrophysiol 2006;17:857-64.
36. Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107:2227-32.
37. Van Driest SL, Ommen SR, Tajik AJ, et al. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clin Proc 2005;80:739-44.
38. Tsatsopoulou AA, Protonotarios NI, McKenna WJ. Arrhythmogenic right ventricular dysplasia, a cell adhesion cardiomyopathy: insights into disease pathogenesis from pleminary genotype-phenotype assessment. Heart 2006;92:1720-3.
39. Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet 2004;36:1162-4.
40. Syrris P, Ward D, Asimaki A, et al. Clinical expression of plakophilin-2 mutations in familial arrhythmogenic right ventricular cardiomyopathy. Circulation 2006;113:356-64.